Terms: = Ovarian cancer AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Treatment
1379 results:
1. Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.
Kong D; Wu Y; Liu Q; Huang C; Wang T; Huang Z; Gao Y; Li Y; Guo H
Eur J Med Res; 2024 Apr; 29(1):231. PubMed ID: 38609993
[TBL] [Abstract] [Full Text] [Related]
2. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast cancer.
Leon-Ferre RA; Jonas SF; Salgado R; Loi S; de Jong V; Carter JM; Nielsen TO; Leung S; Riaz N; Chia S; Jules-Clément G; Curigliano G; Criscitiello C; Cockenpot V; Lambertini M; Suman VJ; Linderholm B; Martens JWM; van Deurzen CHM; Timmermans AM; Shimoi T; Yazaki S; Yoshida M; Kim SB; Lee HJ; Dieci MV; Bataillon G; Vincent-Salomon A; André F; Kok M; Linn SC; Goetz MP; Michiels S;
JAMA; 2024 Apr; 331(13):1135-1144. PubMed ID: 38563834
[TBL] [Abstract] [Full Text] [Related]
3. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.
Yuan H; Li N; Wu L; Yao H
J Ovarian Res; 2024 Apr; 17(1):70. PubMed ID: 38561819
[TBL] [Abstract] [Full Text] [Related]
4. Comparison of the multiples of the median of serum anti-müllerian hormone and pregnancy outcomes in patients with gestational trophoblastic disease: A case-control study.
Lai THT; Lau LSK; Ngu SF; Chu MYM; Chan KKL; Ng EHY; Ngan HYS; Li RHW; Tse KY
Cancer Med; 2024 Apr; 13(7):e7134. PubMed ID: 38545760
[TBL] [Abstract] [Full Text] [Related]
5. Survival of European adolescents and young adults diagnosed with cancer in 2010-2014.
Trama A; Botta L; Stiller C; Visser O; Cañete-Nieto A; Spycher B; Bielska-Lasota M; Katalinic A; Vener C; Innos K; Marcos-Gragera R; Paapsi K; Guevara M; Demuru E; Mousavi SM; Blum M; Eberle A; Ferrari A; Bernasconi A; Lasalvia P;
Eur J Cancer; 2024 May; 202():113558. PubMed ID: 38489859
[TBL] [Abstract] [Full Text] [Related]
6. ovarian Suppression: Early Menopause and Late Effects.
Molinelli C; Jacobs F; Nader-Marta G; Borea R; Scavone G; Ottonello S; Fregatti P; Villarreal-Garza C; Bajpai J; Kim HJ; Puglisi S; de Azambuja E; Lambertini M
Curr Treat Options Oncol; 2024 Apr; 25(4):523-542. PubMed ID: 38478329
[TBL] [Abstract] [Full Text] [Related]
7. Adjuvant ovarian Function Suppression in Premenopausal Hormone Receptor-Positive Breast cancer.
Basmadjian RB; Lupichuk S; Xu Y; Quan ML; Cheung WY; Brenner DR
JAMA Netw Open; 2024 Mar; 7(3):e242082. PubMed ID: 38477918
[TBL] [Abstract] [Full Text] [Related]
8. A clinicopathological study about the epidemiology of granulosa cell tumors in Lebanon.
Yaacoub S; Hajj L; Khairallah A
BMC Cancer; 2024 Mar; 24(1):309. PubMed ID: 38448917
[TBL] [Abstract] [Full Text] [Related]
9. A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Falchook G; Patnaik A; Richardson DL; Harvey RD; Sharma MR; Hafez N; Hamilton E; Piha-Paul SA; Barve M; Wise-Draper T; Patel MR; Dowlati A; Pascuzzo J; Tang SC; Faltermeier C; Malinowska IA; Shtessel L; Striha A; Potocka E
Clin Ther; 2024 Mar; 46(3):228-238. PubMed ID: 38423866
[TBL] [Abstract] [Full Text] [Related]
10. Longitudinal Outcomes of Malignant Ureteral Obstruction Secondary to ovarian cancer: Predictors of Resolution and the Role of Surgical Management.
Faidley KN; Botkin HE; Loeffler BT; Mott SL; Hansen SC; Hill EK; Erickson BA
Urology; 2024 Apr; 186():101-106. PubMed ID: 38350551
[TBL] [Abstract] [Full Text] [Related]
11. BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer.
Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM
Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422
[TBL] [Abstract] [Full Text] [Related]
12. Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Levine MD; Wang H; Sriram B; Khan A; Senter L; McLaughlin EM; Bixel KL; Chambers LM; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Backes FJ
Gynecol Oncol; 2024 Mar; 182():51-56. PubMed ID: 38262238
[TBL] [Abstract] [Full Text] [Related]
13. The comparison of functional status and health-related parameters in ovarian cancer survivors with healthy controls.
Gultekin SC; Cakir AB; Guc ZG; Ozalp FR; Keskinkilic M; Yavuzsen T; Yavuzsen HT; Karadibak D
Support Care Cancer; 2024 Jan; 32(2):119. PubMed ID: 38252310
[TBL] [Abstract] [Full Text] [Related]
14. Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.
Nicum S; McGregor N; Austin R; Collins L; Dutton S; McNeish I; Glasspool R; Hall M; Roux R; Michael A; Clamp A; Jayson G; Kristeleit R; Banerjee S; Mansouri A
Br J Cancer; 2024 Apr; 130(6):941-950. PubMed ID: 38245661
[TBL] [Abstract] [Full Text] [Related]
15. Agricultural exposure and risk of ovarian cancer in the AGRIculture and cancer (AGRICAN) cohort.
Renier M; Hippert J; Louis-Bastien W; Tual S; Meryet-Figuiere M; Vigneron N; Marcotullio E; Baldi I; Lebailly P;
Occup Environ Med; 2024 Feb; 81(2):75-83. PubMed ID: 38199811
[TBL] [Abstract] [Full Text] [Related]
16. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
Wang Y; Dackus GMHE; Rosenberg EH; Cornelissen S; de Boo LW; Broeks A; Brugman W; Chan TWS; van Diest PJ; Hauptmann M; Ter Hoeve ND; Isaeva OI; de Jong VMT; Jóźwiak K; Kluin RJC; Kok M; Koop E; Nederlof PM; Opdam M; Schouten PC; Siesling S; van Steenis C; Voogd AC; Vreuls W; Salgado RF; Linn SC; Schmidt MK
BMC Med; 2024 Jan; 22(1):9. PubMed ID: 38191387
[TBL] [Abstract] [Full Text] [Related]
17. TGF-β-regulated different iron metabolism processes in the development and cisplatin resistance of ovarian cancer.
Wu J; Liao Q; Zhang LI; Wu S; Liu Z
Oncol Res; 2023; 32(2):373-391. PubMed ID: 38186569
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up.
Ju J; Gao SL; Wang JY; Sang D; Kang YK; Wang X; Yue J; Shuai Y; Qi YX; Yuan P
Thorac Cancer; 2024 Feb; 15(6):439-447. PubMed ID: 38185807
[TBL] [Abstract] [Full Text] [Related]
19. A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations.
Vogel A; Haupts A; Kloth M; Roth W; Hartmann N
Diagn Pathol; 2024 Jan; 19(1):9. PubMed ID: 38184614
[TBL] [Abstract] [Full Text] [Related]
20. Phthalimide-tethered isatins as novel poly(ADP-ribose) polymerase inhibitors: Design, synthesis, biological evaluations, and molecular modeling investigations.
El Hassab MA; El-Hafeez AAA; Almahli H; Elsayed ZM; Eldehna WM; Hassan GS; Abou-Seri SM
Arch Pharm (Weinheim); 2024 Mar; 357(3):e2300599. PubMed ID: 38100160
[TBL] [Abstract] [Full Text] [Related]
[Next]